Physician profile
Mark S Kipnes
NPI 1376501965
$31,516.26
in general payments reported to CMS, 2019-2025
69 companies · $2,970 in 2025
The $2,970 reported for 2025 was more than what 83% of Endocrinology, Diabetes & Metabolism providers received nationally (typical 2025 total: $506).
Payments by year
General and research payments by program year, as reported to CMS.
General payments by year: 2019: $8,133 · 2020: $4,523 · 2021: $3,903 · 2022: $3,603 · 2023: $5,763 · 2024: $2,621 · 2025: $2,970.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $7,529 · Consulting Fee: $1,719 · Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program: $1,275 · Travel and Lodging: $831.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $7,528.88 |
| Consulting Fee | $1,718.75 |
| Compensation For Services Other Than Consulting, Including Serving As Faculty Or As A Speaker At A Venue Other Than A Continuing Education Program | $1,275.00 |
| Travel and Lodging | $831.45 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Research payments are listed separately below. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Gilead Sciences, INC. | $4,064.12 | 2019 | |
| Novo Nordisk INC | $3,649.00 | 2019-2025 | Ozempic, Rybelsus, Wegovy |
| Mannkind Corporation | $2,918.38 | 2019-2025 | Afrezza |
| Astrazeneca Pharmaceuticals LP | $1,889.11 | 2019-2023 | Farxiga |
| Lilly USA, LLC | $1,459.19 | 2019-2025 | Jardiance, Mounjaro, Zepbound |
| Radius Health, INC. | $1,274.52 | 2019-2025 | Tymlos |
| Boehringer Ingelheim International Gmbh | $1,243.57 | 2023 | |
| Boehringer Ingelheim Pharmaceuticals, INC. | $1,110.32 | 2019-2024 | Jardiance, Synjardy, Tradjenta |
| Amgen INC. | $1,044.11 | 2019-2024 | Prolia, Evenity, Repatha |
| Tandem Diabetes Care, INC. | $926.79 | 2019-2022 | |
| Abbvie INC. | $825.79 | 2019-2024 | |
| Medtronic, INC. | $825.59 | 2021-2024 | Minimed 780g, Intellis Adaptivestim, Minimed 770g |
| Ascensia Diabetes Care US INC. | $786.42 | 2023-2025 | |
| Xeris Pharmaceuticals, INC. | $748.70 | 2020-2025 | Gvoke Hypopen |
| Corcept Therapeutics | $735.73 | 2020-2025 | Korlym |
Show all 61 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sanofi-Aventis U.S. LLC | $706.94 | 2019-2024 | |
| Amarin Pharma, INC. | $623.86 | 2019-2022 | |
| Antares Pharma, INC. | $590.36 | 2019-2023 | Tlando, Xyosted, Nocdurna |
| Abbott Laboratories | $557.51 | 2019-2025 | Freestyle Libre 3, Freestyle Libre |
| Pfizer INC. | $525.45 | 2019-2024 | |
| Recordati_rare_diseases_inc. | $404.60 | 2021-2025 | Isturisa, Signifor Lar |
| Novartis Pharmaceuticals Corporation | $401.39 | 2021-2024 | |
| Merck Sharp & Dohme LLC | $356.73 | 2019-2022 | |
| Beta Bionics, INC. | $316.26 | 2024-2025 | Ilet Bionic Pancreas, Ilet Insulin Infusion Kit Contact Detach, Ilet Insulin Infusion Kit Inset |
| Zealand Pharma US, INC. | $299.01 | 2020-2022 | |
| Sequel Med Tech, LLC | $295.93 | 2025 | Twiist |
| Valeritas, INC. | $282.83 | 2019 | |
| Esperion Therapeutics, INC. | $273.11 | 2020-2021 | |
| Dexcom, INC. | $271.91 | 2021-2025 | Dexcom G6 Transmitter |
| Medtronic Minimed, INC. | $239.91 | 2019-2020 | |
| Cequr Corporation | $222.83 | 2023-2025 | Cequr Simplicity |
| Bayer Healthcare Pharmaceuticals INC. | $222.37 | 2021-2025 | |
| Becton, Dickinson and Company | $193.55 | 2019-2022 | |
| Ultragenyx Pharmaceutical INC. | $136.93 | 2020-2022 | |
| Insulet Corporation | $130.36 | 2019-2025 | Omnipod |
| Nalpropion Pharmaceuticals LLC | $89.21 | 2019 | |
| Janssen Pharmaceuticals, INC | $74.23 | 2019-2020 | |
| Eusa Pharma (US) LLC | $57.53 | 2022 | |
| Opko Pharmaceuticals, LLC | $55.88 | 2019-2020 | |
| Ipsen Biopharmaceuticals, INC | $54.34 | 2022-2023 | Somatuline Depot |
| Soleno Therapeutics, INC. | $54.24 | 2025 | Vykat Xr |
| Kyowa Kirin, INC. | $53.83 | 2024-2025 | Crysvita |
| Shire North American Group INC | $52.65 | 2019 | |
| Lifescan, INC. | $50.94 | 2020-2022 | |
| Neurocrine Biosciences, INC. | $47.57 | 2024-2025 | |
| Currax Pharmaceuticals LLC | $43.27 | 2020-2021 | |
| Tolmar, INC. | $41.82 | 2023 | |
| Ibsa Pharma INC. | $38.44 | 2020 | |
| Companion Medical, INC. | $26.67 | 2019-2020 | |
| Organogenesis INC. | $24.09 | 2022 | |
| Roche Diabetes Care, INC. | $24.03 | 2019 | |
| Almatica Pharma LLC | $21.96 | 2024 | Teriparatide |
| Halozyme INC | $21.18 | 2023 | |
| Madrigal Pharmaceuticals | $18.72 | 2025 | Rezdiffra |
| Amryt Pharma Holdings LTD | $18.54 | 2021 | |
| Averitas Pharma INC. | $16.81 | 2025 | Qutenza |
| Horizon Therapeutics Plc | $16.64 | 2020 | |
| Nevro Corp. | $16.49 | 2021 | |
| Grt US Holding, INC. | $15.43 | 2021 | |
| Acerus Pharmaceuticals Corporation | $14.36 | 2022 | |
| Intuity Medical INC | $14.21 | 2022 |
8 companies reported research payments only; those appear in the research section below.
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
Research and ownership
$11,624.24 in research payments reported 2019-2025. Research payments are often institution-directed and tied to clinical trials: they are reported under a clinician's name but frequently go to a hospital or research organization, and usually reflect participation in medical research.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Mark Kipnes listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.